Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Schizophrenia and Alcohol Use Disorder
NCT06939088Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Aug 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Change in heavy drinking days at 16 weeks. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06939088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939088.